PIB TrackerFrom pharmacy of the world to laboratory of the world
At the IIMA Healthcare Summit the government put ₹5,000 crore of PRIP and ₹10,000 crore of Biopharma SHAKTI behind research-led pharma, and set a limit on AI: complement clinical judgement, not replace it.
What happened
- The minister called for a shift from 'Pharmacy of the World' to 'Laboratory of the World'.
- AI must complement, not replace, human clinical judgement.
- PRIP carries ₹5,000 crore; Biopharma SHAKTI carries ₹10,000 crore.
- AI Centres of Excellence are at AIIMS New Delhi, PGIMER Chandigarh and AIIMS Rishikesh.
- ABDM reports over 96 crore ABHA IDs and more than 1,000 crore linked health records.
For Prelims
- PRIP: the Promotion of Research and Innovation in Pharma-MedTech Sector scheme — ₹5,000 crore for research and industry-academia collaboration.
- Biopharma SHAKTI: a ₹10,000 crore mission announced in the Union Budget for biologics and biosimilars, manpower and regulatory capacity.
- ABDM: the Ayushman Bharat Digital Mission — an interoperable, open-standards-based digital health ecosystem.
- ABHA: the Ayushman Bharat Health Account identifier — over 96 crore issued, with more than 1,000 crore health records linked.
- eSanjeevani: the national teleconsultation service, cited as having benefited more than 20 crore patients.
- AI Centres of Excellence in health: AIIMS New Delhi, PGIMER Chandigarh and AIIMS Rishikesh.
- AIKosh: the IndiaAI Mission platform for datasets, models and toolkits, cited for democratising access.
- Pandemic record cited: supplies to more than 200 countries and over 2.2 billion vaccine doses administered in India.
For UPSC: A single stage where AI governance, pharmaceutical industrial policy and digital health infrastructure are stated together. Use it for AI in public services, health data governance and the shift from generic manufacturing to research-led pharma.
What it is NOT: This is not a regulatory framework for clinical AI — 'complement, not replace' is a principle stated at a summit, not a rule with an enforcement mechanism.
For Mains
Syllabus: GS3.13 · GS2.13 · Linkage L2
Anchor
India's pharmaceutical advantage was built on making other people's molecules cheaply; discovery asks the same industry to spend heavily on failure, which is a different business model.
Substantiation (data)
₹5,000 crore under PRIP and ₹10,000 crore under Biopharma SHAKTI, AI Centres of Excellence at three public hospitals, over 96 crore ABHA IDs and more than 1,000 crore linked health records.
Exemplification
Startups in Bengaluru and Hyderabad already use AI to shortlist drug candidates while large firms use it for production, marketing and inventory — two adoption curves inside one sector.
Problematisation
The Pharmaceuticals Secretary named the binding constraints himself — capital, software licensing, computing capacity and specialised talent — and none of them is solved by an outlay announcement.
Way-forward
Move the AI Centres of Excellence from pilots to population-level deployment with published accuracy and privacy audits before any screening tool is scaled nationally.
Position
Access to health data, not compute, is the scarce input for India-specific medical AI, and it is the input with the weakest governance.
Deploys into: Biotechnology and IT + health (GS3.13, GS2.13) · AI in healthcare, pharmaceutical research policy and digital health infrastructure.
Ministry of Chemicals and Fertilizers · 2026-08-22 · PRID 2302328 · PIB source ↗